Outlook of drug-eluting stent implantation for unprotected left main disease: insights on long-term clinical predictors

J Invasive Cardiol. 2007 Sep;19(9):381-7.

Abstract

Background: Percutaneous coronary intervention (PCI) has been increasingly employed to treat unprotected left main coronary artery (LMCA) stenosis, with variable success. This strategy has been applied to patients undergoing drug-eluting stent (DES) implantation for unprotected LMCA stenosis.

Methods: From April 2003 to June 2006, 114 consecutive patients with de novo unprotected LMCA stenosis underwent PCI with DES, and were followed over a mean period of 17.1 +/- 9.1 months. The primary endpoint of the study was the occurrence of major adverse cardiovascular events (MACE) (cardiac death, myocardial infarction [MI] or target lesion revascularization [TLR]).

Results: LMCA stenting was successfully performed in all patients. In-hospital mortality was 3.5%, with no in-hospital non-fatal MI or emergency coronary artery bypass grafts. During the follow-up period, the all-cause mortality rate was 7.9%, with 3.5% cardiac-related deaths. TLR was performed in 7.9% of patients, and the MACE rate was 14.9%. All non-surviving patients were at high surgical risk (EuroSCORE > 6) and had a significantly higher EuroSCORE than surviving patients that patients with a EuroSCORE < or = 11 had significantly improved survival rates over those with a EuroSCORE > 11 (p < 0.0001). Moreover, most of the patients who died of cardiac causes were diabetic (71.4% vs. 26.6%; p < 0.05). Acute coronary syndromes, as clinical presentation, and non-ostial LMCA disease were also significantly more common within non-surviving patients (100% vs. 67%; p < 0.05, and 92.3% vs. 66.3%; p = 0.05, respectively).

Conclusions: Stenting of unprotected LMCA appears to be associated with a favorable mid-term outlook, especially in selected patients.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary / mortality*
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Coronary Angiography
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / therapy*
  • Coronary Restenosis / drug therapy
  • Coronary Restenosis / mortality
  • Coronary Restenosis / prevention & control*
  • Drug Delivery Systems
  • Female
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Male
  • Paclitaxel / administration & dosage
  • Predictive Value of Tests
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Sirolimus / administration & dosage*
  • Stents*
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Immunosuppressive Agents
  • Paclitaxel
  • Sirolimus